Developer docs
API playgroundTry for free, no card

Search company profiles

Devyser

Full company profile

uuid0007ith

Namestring
Devyser
Legal namestring
Devyser Diagnostics AB (publ)
Websiteurl
devyser.com
Company typeenum
Public
Founded yearint
2004
Descriptiontext

Devyser Diagnostics AB (publ) is a Stockholm-based molecular diagnostics company founded in 2004 that develops, manufactures, and commercializes DNA diagnostic test kits for clinical laboratories across more than 65 countries. Its portfolio spans next-generation sequencing (NGS) assays and multiplex PCR-based kits organized around five diagnostic areas: post-transplantation monitoring (donor-derived cell-free DNA, chimerism, HLA loss), reproductive health (prenatal aneuploidy, fetal RHD screening, male infertility), hereditary disease testing (cystic fibrosis CFTR, thalassemia), hereditary oncology (BRCA, HBOC, Lynch syndrome), and cardiovascular genetics (thrombophilia, familial hypercholesterolemia). The company's core technical differentiator is a patented single-tube technology that compresses complex multi-step workflows into a single reaction, reducing hands-on time from 1-2 days to approximately 45 minutes and delivering results in 1-2 days versus traditional 4-14 day turnarounds, with chimerism detection sensitivity down to 0.05%.

Devyser generates revenue through three primary streams: direct kit sales via in-house sales offices in Europe and the US (8 offices), exclusive global distribution of transplant products through Thermo Fisher Scientific, and clinical laboratory services from its CLIA-certified Devyser Genomic Laboratories in Roswell, Georgia. A January 2026 strategic supply agreement with Illumina positions Devyser as a systems integrator enabling reagent rental models for sequencing instruments in Europe, creating a recurring revenue stream alongside consumable kit sales. The company complements its kit business with proprietary software products (Advyser Solid Organs, Advyser Chimerism, Amplicon Suite) and follows a tender-and-quote pricing model, with notable contract wins including a five-year SEK 8.9 million regional tender in Italy and a SEK 25 million two-year service agreement with Cyted.

In FY2025, Devyser achieved revenue of SEK 250.5 million with its first positive full-year operating result of SEK 10.1 million, reversing a SEK 62 million loss in 2024, and maintained four consecutive quarters of profitability into Q1 2026 with an 81.6% gross margin. The company is listed on Nasdaq First North Premier Growth Market Stockholm under ticker DVYSR following a December 2021 IPO that raised approximately SEK 300 million. Recent strategic activity includes the April 2026 acquisition of CyberGene AB for SEK 12.2 million, multiple IVDR Class C certifications including the first IVDR-compliant NGS thalassemia assay, and leadership transitions with Jan Wahlström appointed CEO in August 2025.

Short descriptiontext

Devyser Diagnostics AB is a Stockholm-based molecular diagnostics company that develops and sells NGS and PCR-based DNA test kits to clinical laboratories in 65+ countries, with primary focus on post-transplantation monitoring, reproductive health, hereditary disease, and oncology testing. The company also operates a CLIA-certified laboratory in the US and is listed on Nasdaq First North Stockholm under ticker DVYSR.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genetic diagnostic kits, NGS clinical assays, molecular diagnostics, transplant monitoring tests, prenatal genetic testing
Industry6 codes
PRIMARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
NAICS code4 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • Medical and Diagnostic Laboratories62151
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code3 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Molecular Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic kit sales
TypeHardware Sales
Description

Devyser develops, manufactures, and sells DNA diagnostic test kits to clinical laboratories. Products include NGS assays, fragment analysis kits, and related reagents. Revenue is generated through direct sales and distributor relationships across 65+ countries.

devyser.com
2Sequencing instruments and products
TypeHardware Sales
Description

Through strategic agreement with Illumina, Devyser provides sequencing instruments and related products to customers, enabling reagent rental models rather than traditional capital purchases.

devyser.com
3Laboratory services
TypeProfessional Services
Description

Devyser Genomic Laboratories, a CLIA-certified laboratory in Atlanta, offers clinical testing services to hospitals, laboratories, and pharmaceutical partners. Revenue from service agreements with partners like Cyted (estimated SEK 25 million over 2 years).

investors.devyser.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Five-year tender covering multiple diagnostic products
ModelOtherBilling cadenceMulti-year contract
Notes

Tender in Regione Basilicata, Italy valued at SEK 8.9 million total over 5 years. Covers CFTR-related disorders, thalassemia, chromosomal aneuploidy, and male infertility products.

devyser.com
2PrenatalDetect RHD test pricing
ModelOtherBilling cadencePay-as-you-go
Notes

CMS has set price for Devyser's PrenatalDetect RHD test in US market.

marketscreener.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Cybergene ChromoQuant®
Description

Product brand under CyberGene for prenatal, pregnancy loss, and male infertility diagnostics.

devyser.com
+4 more records
Core offering1 text field

Devyser develops, manufactures, and sells DNA diagnostic test kits based on next-generation sequencing (NGS) and multiplex PCR technologies for clinical laboratories worldwide. Its portfolio covers post-transplantation monitoring (dd-cfDNA, chimerism, HLA loss), hereditary cancer screening (BRCA, Lynch syndrome), prenatal diagnostics (aneuploidy, fetal RHD), cystic fibrosis, thalassemia, cardiovascular diseases, and male infertility. The company also operates a CLIA-certified laboratory in Atlanta offering clinical testing services and proprietary analysis software (Advyser, Amplicon Suite).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Hands-on time reduced from 1-2 days to ~45 minutes
+5 more records
Product overview1 text field

Devyser is a pioneering provider of diagnostic DNA test kits and genetic testing solutions for clinical laboratories. The company offers a comprehensive portfolio of NGS-based and PCR-based diagnostic products organized across multiple diagnostic areas: post-transplantation monitoring (chimerism, cfDNA, HLA loss), oncology (hereditary cancer panels for BRCA, Lynch syndrome), reproductive health (prenatal aneuploidy detection, fetal RHD screening, male infertility), cystic fibrosis (CFTR testing), and cardiovascular diseases (thrombophilia, familial hypercholesterolemia). Devyser's products include rapid aneuploidy tests (Devyser Compact, Complete, Extend, Resolution series), comprehensive NGS assays (Thalassemia, CFTR, BRCA, HBOC, LynchFAP), and transplantation monitoring solutions (Accept cfDNA, Chimerism NGS, HLA Loss). The portfolio is complemented by software products (Advyser Solid organs, Advyser Chimerism, Amplicon Suite) for data analysis and interpretation. Following the 2026 acquisition of CyberGene, the portfolio expanded to include Cybergene ChromoQuant products for prenatal, pregnancy loss, and male infertility diagnostics. Devyser also operates Devyser Genomic Laboratories, a CLIA-certified service laboratory in Atlanta, and provides laboratory services to pharmaceutical companies. Products are distributed in 65+ countries through direct sales offices in Europe and the US, as well as distribution partnerships including Thermo Fisher Scientific for transplantation products globally and Illumina for MiSeqDx platform integration.

Product and service25 records
1One Lambda Devyser Accept cfDNA
CategoryPost-Transplantation Diagnostic Kits
Description

Single-tube NGS assay for detection of donor-derived cell-free DNA (dd-cfDNA) in blood samples from kidney transplant patients with high sensitivity for monitoring organ damage and rejection.

2One Lambda Devyser Chimerism NGS
CategoryPost-Transplantation Diagnostic Kits
Description

NGS assay for measuring chimerism accurately down to 0.05% minority fraction for screening and follow-up of stem cell transplanted patients.

3Devyser HLA Loss
CategoryPost-Transplantation Diagnostic Kits
Description

High-precision NGS assay for detecting HLA loss in mismatched transplant settings, designed exclusively for post-transplantation research use.

4Devyser Compact
CategoryRapid Aneuploidy Diagnostic Kits
Description

Rapid genetic test for prenatal chromosome testing using single-tube PCR for detecting fetal chromosomal abnormalities including Down syndrome and Turner syndrome.

5Devyser Complete
6Devyser RHD
7Devyser Thalassemia NGS
8Devyser Thalassemia v2
CategoryHereditary Disease Diagnostic Kits
Description

First IVDR-compliant NGS assay for genetic analysis of thalassemia and sickle cell disease in a single consolidated workflow, with Class C certification under EU IVDR.

9Devyser CFTR NGS
CategoryCystic Fibrosis Diagnostic Kits
Description

Complete sequencing of CFTR gene to detect all mutations including the 100 variants from ACMG recommendations in a single assay for cystic fibrosis diagnosis.

10Devyser BRCA NGS
CategoryHereditary Cancer Diagnostic Kits
Description

NGS assay for detecting all mutations in BRCA1 and BRCA2 genes for hereditary breast cancer risk assessment.

11Devyser HBOC NGS
CategoryHereditary Cancer Diagnostic Kits
Description

NGS assay for hereditary breast and ovarian cancer gene panel testing.

12Devyser BRCA PALB2 NGS
CategoryHereditary Cancer Diagnostic Kits
Description

NGS assay for detection of sequence variants in BRCA1, BRCA2 and PALB2 genes associated with hereditary cancer risk.

13Devyser LynchFAP
CategoryHereditary Cancer Diagnostic Kits
Description

NGS solution for confident localization of variants in all exons of PMS2 gene for Lynch syndrome and FAP diagnostics.

14Devyser AZF Extension
CategoryMale Infertility Diagnostic Kits
Description

Y-chromosomal microdeletion test for male infertility diagnostics, updated to latest 2023 EQA guidelines.

15Devyser AZF v2
CategoryMale Infertility Diagnostic Kits
Description

Updated Y-chromosomal microdeletion test for male infertility diagnostics.

16Devyser Thrombophilia
CategoryCardiovascular Disease Diagnostic Kits
Description

Genetic test for thrombophilia risk assessment in cardiovascular diseases.

17Devyser FH NGS
CategoryCardiovascular Disease Diagnostic Kits
Description

NGS assay for familial hypercholesterolemia diagnosis and cascade screening.

18Devyser CVD
CategoryCardiovascular Disease Diagnostic Kits
Description

Cardiovascular disease genetic testing solution for monogenic and polygenic familial conditions.

19Devyser Genomic Blood Typing
CategoryTransfusion Medicine Diagnostic Kits
Description

Genomic blood typing solution for transfusion medicine applications.

20Devyser CFTR Core
CategoryCystic Fibrosis Diagnostic Kits
Description

Fragment analysis test for CFTR gene mutations used for screening and confirmation of cystic fibrosis.

21Cybergene ChromoQuant
CategoryPrenatal and Infertility Diagnostic Kits (Acquired Brand)
Description

Product line from acquired CyberGene AB covering prenatal diagnostics, pregnancy loss diagnostics, and male infertility diagnostics using ChromoQuant technology.

22Advyser Solid Organs
CategoryGenetic Analysis Software
Description

IVDR-certified software for monitoring donor-derived cell-free DNA (dd-cfDNA) in patients following kidney transplantation, intended for use with One Lambda Devyser Accept cfDNA.

23Advyser Chimerism
CategoryGenetic Analysis Software
Description

Software for chimerism analysis data interpretation for stem cell transplantation monitoring.

24Amplicon Suite
CategoryGenetic Analysis Software
Description

Software for genetic data analysis, acquired through SmartSeq S.r.l. acquisition, enabling Devyser to supply the software independently.

25Devyser Genomic Laboratories
CategoryClinical Laboratory Services
Description

CLIA-certified and CAP-accredited laboratory in Atlanta, Georgia offering clinical test services for hereditary diseases, oncology, and post-transplant monitoring, and providing laboratory services to pharmaceutical companies for research support.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-28
Description

Strategic supply agreement where Devyser provides Illumina sequencing instruments and related products to customers. Devyser acts as systems integrator for European reagent rental market. Also includes IVD development agreement for regulatory registrations of Devyser's NGS tests on MiSeqDx platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-29
Description

Collaboration with Thermo Fisher Scientific to obtain FDA approval for One Lambda Devyser Accept cfDNA, a cobranded NGS solution for detecting donor-derived cell-free DNA in kidney transplant patients. Thermo Fisher is exclusive global distributor of Devyser's transplantation products.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-02-29
Description

Collaborative study with Departments of Immunology and Nephrology at University of Zurich, including Dr. Jakob Nilsson, using One Lambda Devyser Accept cfDNA assay. Published article demonstrating dd-cfDNA detection in dual donor kidney transplant patients.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-17
Description

First commercial agreement for Devyser Genomic Laboratories. Cyted will use Devyser's CLIA-certified laboratory services for their Heartburn Health Check using EndoSign test in US markets. Initial period of 2 years with estimated revenue of SEK 25 million.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-01-08
Description

IVD development agreement enabling Devyser to develop and offer its in vitro diagnostic tests on Illumina MiSeqDx NGS instrument in US and Europe. Allows regulatory registrations of Devyser's tests on FDA-regulated and CE-IVD-marked sequencing platform.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-09-13
Description

Collaboration agreement to promote laboratory services. Goal is to partner with pharmaceutical companies to support their development projects using Devyser's assays at the CLIA-certified laboratory.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-04-24
Description

Exclusive collaboration and distribution agreement where Thermo Fisher markets and sells Devyser's post-transplant monitoring products (One Lambda Devyser Accept cfDNA and One Lambda Devyser Chimerism) under combined brands. Originally covered North America and Europe, expanded in September 2023 to include Brazil. This is a major channel partnership for Devyser's transplant diagnostics portfolio.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CareDx is the US leader in transplant diagnostics with AlloSure dd-cfDNA and AlloMap. It is the closest direct competitor to Devyser's One Lambda Devyser Accept cfDNA and chimerism assays, targeting the same transplant nephrology and hematology customers with NGS-based surveillance.

TypeBroad incumbent
Description

QIAGEN is a global molecular diagnostics and sample-preparation technology company with broad IVD, PCR, and NGS-adjacent offerings. While not specialized in transplant, it serves the same clinical lab customers as Devyser with overlapping reagent and assay products.

TypeBroad incumbent
Description

NeoGenomics is a US-based oncology and molecular diagnostics laboratory and kit provider. It overlaps with Devyser on hereditary cancer (BRCA, Lynch) NGS kits and on clinical testing services for transplant and oncology through its lab footprint.

TypeBroad incumbent
Description

Revvity (formerly PerkinElmer Life Sciences) provides genetic screening reagents, newborn screening platforms, and reproductive health diagnostics. Its maternal-fetal health and clinical lab reagent offerings overlap with Devyser's prenatal and hereditary disease kit portfolio.

TypeBroad incumbent
Description

Bio-Techne's Diagnostics & Genomics segment sells molecular biology reagents, exo-RNA and protein assays, and diagnostic kits to clinical and research labs. Its reagent catalog and clinical lab partnerships overlap with Devyser's NGS-based diagnostic workflow offerings.

TypeDirect peer
Description

Eurofins Genomics operates genetic testing services and kit manufacturing across Europe, including prenatal, hereditary disease, and transplant-adjacent assays. It is a comparable European diagnostics platform with both kit and laboratory services offerings overlapping Devyser.

TypeDirect peer
Description

Centogene provides rare disease genetic diagnostics, including thalassemia, cystic fibrosis, and prenatal screening. It overlaps with Devyser on CFTR, thalassemia, and hereditary disease kit portfolios, particularly in EMEA markets.

TypeDirect peer
Description

Invitae is a genetic testing services and kit provider covering hereditary cancer, reproductive health, and rare disease panels. Although currently undergoing restructuring, its menu directly competes with Devyser's hereditary cancer, CFTR, and prenatal offerings to clinical labs.

TypeDirect peer
Description

Myriad offers hereditary cancer (BRCA, Lynch), prenatal (Prequel NIPT), and molecular diagnostics. It overlaps with Devyser on BRCA NGS, Lynch syndrome testing, and reproductive health screening sold to clinical labs and providers.

TypeDirect peer
Description

Natera is a DNA-based testing company with Prospera dd-cfDNA for transplant monitoring, Vistara for NIPT, and Empower for hereditary cancer. It directly overlaps Devyser across transplant, reproductive health, and hereditary disease segments using cfDNA and NGS technologies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance12 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Devyser

Molecular Diagnosticsdevyser.com

Devyser Diagnostics AB is a Stockholm-based molecular diagnostics company that develops and sells NGS and PCR-based DNA test kits to clinical laboratories in 65+ countries, with primary focus on post-transplantation monitoring, reproductive health, hereditary disease, and oncology testing. The company also operates a CLIA-certified laboratory in the US and is listed on Nasdaq First North Stockholm under ticker DVYSR.

What Devyser does

Devyser Diagnostics AB (publ) is a Stockholm-based molecular diagnostics company founded in 2004 that develops, manufactures, and commercializes DNA diagnostic test kits for clinical laboratories across more than 65 countries. Its portfolio spans next-generation sequencing (NGS) assays and multiplex PCR-based kits organized around five diagnostic areas: post-transplantation monitoring (donor-derived cell-free DNA, chimerism, HLA loss), reproductive health (prenatal aneuploidy, fetal RHD screening, male infertility), hereditary disease testing (cystic fibrosis CFTR, thalassemia), hereditary oncology (BRCA, HBOC, Lynch syndrome), and cardiovascular genetics (thrombophilia, familial hypercholesterolemia). The company's core technical differentiator is a patented single-tube technology that compresses complex multi-step workflows into a single reaction, reducing hands-on time from 1-2 days to approximately 45 minutes and delivering results in 1-2 days versus traditional 4-14 day turnarounds, with chimerism detection sensitivity down to 0.05%.

Devyser generates revenue through three primary streams: direct kit sales via in-house sales offices in Europe and the US (8 offices), exclusive global distribution of transplant products through Thermo Fisher Scientific, and clinical laboratory services from its CLIA-certified Devyser Genomic Laboratories in Roswell, Georgia. A January 2026 strategic supply agreement with Illumina positions Devyser as a systems integrator enabling reagent rental models for sequencing instruments in Europe, creating a recurring revenue stream alongside consumable kit sales. The company complements its kit business with proprietary software products (Advyser Solid Organs, Advyser Chimerism, Amplicon Suite) and follows a tender-and-quote pricing model, with notable contract wins including a five-year SEK 8.9 million regional tender in Italy and a SEK 25 million two-year service agreement with Cyted.

In FY2025, Devyser achieved revenue of SEK 250.5 million with its first positive full-year operating result of SEK 10.1 million, reversing a SEK 62 million loss in 2024, and maintained four consecutive quarters of profitability into Q1 2026 with an 81.6% gross margin. The company is listed on Nasdaq First North Premier Growth Market Stockholm under ticker DVYSR following a December 2021 IPO that raised approximately SEK 300 million. Recent strategic activity includes the April 2026 acquisition of CyberGene AB for SEK 12.2 million, multiple IVDR Class C certifications including the first IVDR-compliant NGS thalassemia assay, and leadership transitions with Jan Wahlström appointed CEO in August 2025.

Devyser firmographics

Firmographics
Name
Devyser
Legal name
Devyser Diagnostics AB (publ)
Website
https://devyser.com
Company type
Public
Founded year
2004
Operating status
Operating
Headcount range
101–250 employees
Short description
Devyser Diagnostics AB is a Stockholm-based molecular diagnostics company that develops and sells NGS and PCR-based DNA test kits to clinical laboratories in 65+ countries, with primary focus on post-transplantation monitoring, reproductive health, hereditary disease, and oncology testing. The company also operates a CLIA-certified laboratory in the US and is listed on Nasdaq First North Stockholm under ticker DVYSR.
Ownership category
akta.pro rank

Devyser industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)

Keywords

  • Genetic diagnostic kits
  • NGS clinical assays
  • Molecular diagnostics
  • Transplant monitoring tests
  • Prenatal genetic testing

Where Devyser is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Offices4 records

Markets served

Devyser business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic kit sales: Devyser develops, manufactures, and sells DNA diagnostic test kits to clinical laboratories. Products include NGS assays, fragment analysis kits, and related reagents. Revenue is generated through direct sales and distributor relationships across 65+ countries.
  2. Sequencing instruments and products: Through strategic agreement with Illumina, Devyser provides sequencing instruments and related products to customers, enabling reagent rental models rather than traditional capital purchases.
  3. Laboratory services: Devyser Genomic Laboratories, a CLIA-certified laboratory in Atlanta, offers clinical testing services to hospitals, laboratories, and pharmaceutical partners. Revenue from service agreements with partners like Cyted (estimated SEK 25 million over 2 years).

Pricing tiers

ModelBillingPrice
OtherMulti-year contractFive-year tender covering multiple diagnostic products
OtherPay-as-you-goPrenatalDetect RHD test pricing

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Devyser product offering

Product offering

Core offering

Devyser develops, manufactures, and sells DNA diagnostic test kits based on next-generation sequencing (NGS) and multiplex PCR technologies for clinical laboratories worldwide. Its portfolio covers post-transplantation monitoring (dd-cfDNA, chimerism, HLA loss), hereditary cancer screening (BRCA, Lynch syndrome), prenatal diagnostics (aneuploidy, fetal RHD), cystic fibrosis, thalassemia, cardiovascular diseases, and male infertility. The company also operates a CLIA-certified laboratory in Atlanta offering clinical testing services and proprietary analysis software (Advyser, Amplicon Suite).

Product overview

Devyser is a pioneering provider of diagnostic DNA test kits and genetic testing solutions for clinical laboratories. The company offers a comprehensive portfolio of NGS-based and PCR-based diagnostic products organized across multiple diagnostic areas: post-transplantation monitoring (chimerism, cfDNA, HLA loss), oncology (hereditary cancer panels for BRCA, Lynch syndrome), reproductive health (prenatal aneuploidy detection, fetal RHD screening, male infertility), cystic fibrosis (CFTR testing), and cardiovascular diseases (thrombophilia, familial hypercholesterolemia). Devyser's products include rapid aneuploidy tests (Devyser Compact, Complete, Extend, Resolution series), comprehensive NGS assays (Thalassemia, CFTR, BRCA, HBOC, LynchFAP), and transplantation monitoring solutions (Accept cfDNA, Chimerism NGS, HLA Loss). The portfolio is complemented by software products (Advyser Solid organs, Advyser Chimerism, Amplicon Suite) for data analysis and interpretation. Following the 2026 acquisition of CyberGene, the portfolio expanded to include Cybergene ChromoQuant products for prenatal, pregnancy loss, and male infertility diagnostics. Devyser also operates Devyser Genomic Laboratories, a CLIA-certified service laboratory in Atlanta, and provides laboratory services to pharmaceutical companies. Products are distributed in 65+ countries through direct sales offices in Europe and the US, as well as distribution partnerships including Thermo Fisher Scientific for transplantation products globally and Illumina for MiSeqDx platform integration.

Differentiator

Problem solved

Functional benefit

Brands

  • Cybergene ChromoQuant®: Product brand under CyberGene for prenatal, pregnancy loss, and male infertility diagnostics.
  • Advyser Solid organs
  • Advyser Chimerism
  • Amplicon Suite
  • Devyser Genomic Laboratories

Products and services

  • One Lambda Devyser Accept cfDNA Single-tube NGS assay for detection of donor-derived cell-free DNA (dd-cfDNA) in blood samples from kidney transplant patients with high sensitivity for monitoring organ damage and rejection.
  • One Lambda Devyser Chimerism NGS NGS assay for measuring chimerism accurately down to 0.05% minority fraction for screening and follow-up of stem cell transplanted patients.
  • Devyser HLA Loss High-precision NGS assay for detecting HLA loss in mismatched transplant settings, designed exclusively for post-transplantation research use.
  • Devyser Compact Rapid genetic test for prenatal chromosome testing using single-tube PCR for detecting fetal chromosomal abnormalities including Down syndrome and Turner syndrome.
  • Devyser Complete
  • Devyser RHD
  • Devyser Thalassemia NGS
  • Devyser Thalassemia v2 First IVDR-compliant NGS assay for genetic analysis of thalassemia and sickle cell disease in a single consolidated workflow, with Class C certification under EU IVDR.
  • Devyser CFTR NGS Complete sequencing of CFTR gene to detect all mutations including the 100 variants from ACMG recommendations in a single assay for cystic fibrosis diagnosis.
  • Devyser BRCA NGS NGS assay for detecting all mutations in BRCA1 and BRCA2 genes for hereditary breast cancer risk assessment.
  • Devyser HBOC NGS NGS assay for hereditary breast and ovarian cancer gene panel testing.
  • Devyser BRCA PALB2 NGS NGS assay for detection of sequence variants in BRCA1, BRCA2 and PALB2 genes associated with hereditary cancer risk.
  • Devyser LynchFAP NGS solution for confident localization of variants in all exons of PMS2 gene for Lynch syndrome and FAP diagnostics.
  • Devyser AZF Extension Y-chromosomal microdeletion test for male infertility diagnostics, updated to latest 2023 EQA guidelines.
  • Devyser AZF v2 Updated Y-chromosomal microdeletion test for male infertility diagnostics.
  • Devyser Thrombophilia Genetic test for thrombophilia risk assessment in cardiovascular diseases.
  • Devyser FH NGS NGS assay for familial hypercholesterolemia diagnosis and cascade screening.
  • Devyser CVD Cardiovascular disease genetic testing solution for monogenic and polygenic familial conditions.
  • Devyser Genomic Blood Typing Genomic blood typing solution for transfusion medicine applications.
  • Devyser CFTR Core Fragment analysis test for CFTR gene mutations used for screening and confirmation of cystic fibrosis.
  • Cybergene ChromoQuant Product line from acquired CyberGene AB covering prenatal diagnostics, pregnancy loss diagnostics, and male infertility diagnostics using ChromoQuant technology.
  • Advyser Solid Organs IVDR-certified software for monitoring donor-derived cell-free DNA (dd-cfDNA) in patients following kidney transplantation, intended for use with One Lambda Devyser Accept cfDNA.
  • Advyser Chimerism Software for chimerism analysis data interpretation for stem cell transplantation monitoring.
  • Amplicon Suite Software for genetic data analysis, acquired through SmartSeq S.r.l. acquisition, enabling Devyser to supply the software independently.
  • Devyser Genomic Laboratories CLIA-certified and CAP-accredited laboratory in Atlanta, Georgia offering clinical test services for hereditary diseases, oncology, and post-transplant monitoring, and providing laboratory services to pharmaceutical companies for research support.

Quantifiable outcome

  • Hands-on time reduced from 1-2 days to ~45 minutes
  • +5 more outcomes

Companies that use Devyser

Customer profile

Named customers6 records

Segments6 records

Ideal customer profiles4 records

Devyser technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Devyser partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • IlluminacoreTechnology or Integration · 28 January 2026Strategic supply agreement where Devyser provides Illumina sequencing instruments and related products to customers. Devyser acts as systems integrator for European reagent rental market. Also includes IVD development agreement for regulatory registrations of Devyser's NGS tests on MiSeqDx platform.
  • Thermo Fisher ScientificcoreStrategic or Co-development Partner · 29 October 2024Collaboration with Thermo Fisher Scientific to obtain FDA approval for One Lambda Devyser Accept cfDNA, a cobranded NGS solution for detecting donor-derived cell-free DNA in kidney transplant patients. Thermo Fisher is exclusive global distributor of Devyser's transplantation products.
  • University of ZurichminorStrategic or Co-development Partner · 29 February 2024Collaborative study with Departments of Immunology and Nephrology at University of Zurich, including Dr. Jakob Nilsson, using One Lambda Devyser Accept cfDNA assay. Published article demonstrating dd-cfDNA detection in dual donor kidney transplant patients.
  • CytedminorStrategic or Co-development Partner · 17 January 2024First commercial agreement for Devyser Genomic Laboratories. Cyted will use Devyser's CLIA-certified laboratory services for their Heartburn Health Check using EndoSign test in US markets. Initial period of 2 years with estimated revenue of SEK 25 million.
  • IlluminacoreTechnology or Integration · 8 January 2024IVD development agreement enabling Devyser to develop and offer its in vitro diagnostic tests on Illumina MiSeqDx NGS instrument in US and Europe. Allows regulatory registrations of Devyser's tests on FDA-regulated and CE-IVD-marked sequencing platform.
  • Thermo Fisher ScientificminorStrategic or Co-development Partner · 13 September 2023Collaboration agreement to promote laboratory services. Goal is to partner with pharmaceutical companies to support their development projects using Devyser's assays at the CLIA-certified laboratory.
  • Thermo Fisher ScientificcoreChannel Partner/ Reseller/ Distributor · 24 April 2023Exclusive collaboration and distribution agreement where Thermo Fisher markets and sells Devyser's post-transplant monitoring products (One Lambda Devyser Accept cfDNA and One Lambda Devyser Chimerism) under combined brands. Originally covered North America and Europe, expanded in September 2023 to include Brazil. This is a major channel partnership for Devyser's transplant diagnostics portfolio.

Scale indicators14 records

Recent moves8 records

Expansion highlights6 records

Devyser competitors and assessment

Company assessment

Direct peers

  • CareDx: CareDx is the US leader in transplant diagnostics with AlloSure dd-cfDNA and AlloMap. It is the closest direct competitor to Devyser's One Lambda Devyser Accept cfDNA and chimerism assays, targeting the same transplant nephrology and hematology customers with NGS-based surveillance.
  • Eurofins Genomics: Eurofins Genomics operates genetic testing services and kit manufacturing across Europe, including prenatal, hereditary disease, and transplant-adjacent assays. It is a comparable European diagnostics platform with both kit and laboratory services offerings overlapping Devyser.
  • Centogene: Centogene provides rare disease genetic diagnostics, including thalassemia, cystic fibrosis, and prenatal screening. It overlaps with Devyser on CFTR, thalassemia, and hereditary disease kit portfolios, particularly in EMEA markets.
  • Invitae: Invitae is a genetic testing services and kit provider covering hereditary cancer, reproductive health, and rare disease panels. Although currently undergoing restructuring, its menu directly competes with Devyser's hereditary cancer, CFTR, and prenatal offerings to clinical labs.
  • Myriad Genetics: Myriad offers hereditary cancer (BRCA, Lynch), prenatal (Prequel NIPT), and molecular diagnostics. It overlaps with Devyser on BRCA NGS, Lynch syndrome testing, and reproductive health screening sold to clinical labs and providers.
  • Natera: Natera is a DNA-based testing company with Prospera dd-cfDNA for transplant monitoring, Vistara for NIPT, and Empower for hereditary cancer. It directly overlaps Devyser across transplant, reproductive health, and hereditary disease segments using cfDNA and NGS technologies.

Broad incumbents

  • QIAGEN: QIAGEN is a global molecular diagnostics and sample-preparation technology company with broad IVD, PCR, and NGS-adjacent offerings. While not specialized in transplant, it serves the same clinical lab customers as Devyser with overlapping reagent and assay products.
  • NeoGenomics: NeoGenomics is a US-based oncology and molecular diagnostics laboratory and kit provider. It overlaps with Devyser on hereditary cancer (BRCA, Lynch) NGS kits and on clinical testing services for transplant and oncology through its lab footprint.
  • Revvity: Revvity (formerly PerkinElmer Life Sciences) provides genetic screening reagents, newborn screening platforms, and reproductive health diagnostics. Its maternal-fetal health and clinical lab reagent offerings overlap with Devyser's prenatal and hereditary disease kit portfolio.
  • Bio-Techne: Bio-Techne's Diagnostics & Genomics segment sells molecular biology reagents, exo-RNA and protein assays, and diagnostic kits to clinical and research labs. Its reagent catalog and clinical lab partnerships overlap with Devyser's NGS-based diagnostic workflow offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Devyser social profiles

Digital presence

Devyser compliance and trust

Trust signal

Compliance12 records

Devyser financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Devyser leadership team

Management profile

Number of profiles

Profiles6 records

Devyser subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Devyser funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Devyser M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Devyser

What does Devyser do?

Devyser develops, manufactures, and sells DNA diagnostic test kits based on next-generation sequencing (NGS) and multiplex PCR technologies for clinical laboratories worldwide. Its portfolio covers post-transplantation monitoring (dd-cfDNA, chimerism, HLA loss), hereditary cancer screening (BRCA, Lynch syndrome), prenatal diagnostics (aneuploidy, fetal RHD), cystic fibrosis, thalassemia, cardiovascular diseases, and male infertility. The company also operates a CLIA-certified laboratory in Atlanta offering clinical testing services and proprietary analysis software (Advyser, Amplicon Suite).

Is Devyser a public or private company?

Devyser is a public company. It is classified as public and is currently operating.

When was Devyser founded?

Devyser was founded in 2004. It employs 101 to 250 people.

Where is Devyser based?

Devyser is headquartered in Stockholm, Sweden, in the Europe region.

How does Devyser make money?

Three revenue lines are on record. Diagnostic kit sales are the primary driver. The others are sequencing instruments and products and laboratory services.

Who are Devyser's main competitors?

Direct peers on record are CareDx, Eurofins Genomics, Centogene, Invitae, Myriad Genetics and Natera. Broad incumbents are QIAGEN, NeoGenomics, Revvity and Bio-Techne.

Does Devyser have an API?

No public API is recorded for Devyser.

What industry is Devyser in?

Devyser's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comDevyser Q3 2026 slides: profit jumps as margins recover to 83%Devyser reported Q3 2026 revenue of 59.7 million SEK, up 5.8% year-over-year, with EBIT jumping to 7.1 million SEK from 1.3 million. Gross margin recovered to 83% from 75%, and operating cash flow turned positive at 22.0 million SEK. Management expects distributor inventory normalization to ease in 2027.Seeking AlphaDevyser Diagnostics AB (publ) (DVYSF) Q3 2026 Earnings Call TranscriptDevyser Diagnostics reported materially improved profitability in Q3 2026, with gross margin returning to 83% after a one-off inventory effect. EBIT increased significantly, and the company cited enhanced organizational efficiency and cost discipline. The call also covered recent commercial activities.TradingViewDevyser Diagnostics Q3 2026 Earnings Call Is LiveDevyser Diagnostics' Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. Management commentary on future demand, margins, or capital spending may move markets.TradingViewDevyser Diagnostics AB (DVYSR) Reports Q3 Sales Drag and Improved ProfitabilityDevyser Diagnostics reported Q3 sales were weighed down by its largest distributor's inventory adjustment, which is expected to affect Q4. Profitability improved year over year in both Q3 and January–September, though no figures were disclosed. Sales to the distributor are expected to gradually normalize from 2027.The future of tradingDevyser extends its transplant test to heart and lung patientsDevyser announced that its One Lambda Devyser Accept cfDNA test can now monitor heart and lung transplant recipients, in addition to kidney patients. The IVDR-compliant solution, developed with Thermo Fisher Scientific, uses donor-derived cell-free DNA to detect graft injury. Results are available within two days, expanding the test's market reach.The future of tradingDevyser Diagnostics announces Q3 2026 results presentationDevyser Diagnostics will publish its third-quarter 2026 interim report on November 3 at 7:30 a.m. CET, followed by an online results presentation at 9 a.m. CET. The company is expected to report financial results for the quarter.TradingViewInvitation to Devyser’s Q3 2026 results presentationDevyser Diagnostics will host an online presentation of its Q3 2026 interim report on November 3 at 09:00 CET, with the report published at 07:30 CET. CEO Jan Wahlström and CFO Niklas Axelsson will speak, and the presentation is available via webcast or teleconference.YahooDevyser Diagnostics AB (STU:OL0) Q2 2026 Earnings Call Highlights: Navigating Revenue ...Devyser Diagnostics AB reported Q2 2026 revenue of SEK60 million, an 11% decline year-over-year, though the company achieved its fifth consecutive quarter of positive EBIT at SEK0.5 million amid a one-off inventory impact that reduced gross margin to 76%. The company finalized the CyberGene acquisition, grew direct sales by 14%, and secured a SEK70 million loan agreement with SEB, while anticipating a weaker second half with return to growth not expected until 2027.Seeking AlphaDevyser Diagnostics AB (publ) (DVYSF) Q2 2026 Earnings Call TranscriptDevyser Diagnostics AB reported a sales setback in Q2 2026 due to lower-than-expected sales to its biggest distributor, with weak transplant product sales as lab onboarding took longer than anticipated. Despite the sales shortfall, the company achieved positive EBIT for the fifth consecutive quarter and maintained a gross margin in line with its 80% target. Management expressed confidence in achieving strong growth in 2027 as volume buildup delays are resolved.AffarsvarldenStockholmsbörsen öppnar veckan nedåtThe Stockholm Stock Exchange opened lower on Monday morning, with the OMXS30 index falling 0.30% to 3,137.47 points as of 09:22. Among large-cap stocks, Thule was the biggest mover after reporting Q2 adjusted operating profit in line with expectations at 779 million SEK while announcing planned price increases in Q3 to offset rising raw material costs, sending its shares down 5.3%. Devyser also stood out with weaker Q2 sales and earnings due to a major distributor reducing inventory purchases, though the company expects demand to normalize from 2027 onward.